Patent ID: 6872381

Claim:
A method of diagnosing Alzheimer's disease in a human patient which comprises: administering to a patient in need of such diagnosis a compound according to of formula (I): wherein: X 1 and X 2 are each independently halo; R 1 and R 2 are each independently hydrogen or alkyl; and R 3 is hydrogen, amino, monoalkylamino, dialkylamino, monoaralkylamino, alkylcarbonylanmino, alkenylcarbonylamino, haloalkylcarbonylamino, arylcarbonylamino, alkoxyalkylcarbonylamino, alkoxycarbonylalkylcarbonylamino, glycinamido, monoalkylglycinamido, arylcarbonylglycinamido, aminocarbonylglycinamido, (aminocarbonyl)(alkyl)glycinamido, (alkoxyalkylcarbonyl)glycinamido, ureido, monoalkylureido, monoarylureido, monoaralkylureido, or alaninamido; and wherein either one of X 1 or X 2 is selected from the group of 123 I, 125 I, 128 I, 131 I, 75 Br, 76 Br, 80 Br and 18 F; or wherein one of the carbon atoms in the compound is 11 C; or a pharmaceutically acceptable salt thereof, and measuring the radioactivity arising from the administration of the compound to said patient either by using a gamma camera or by positron emission tomography (PET).